Gunilla Lundmark was appointed new chief executive officer (CEO) of Pharmanest AB. She is currently Senior Executive Vice President at Q-Med. Gunilla Lundmark will begin in her new position in January, 2011. Pharmanest?s previous CEO, Anders Åsell, decided to leave Pharmanest for a position as head of the Spanish company, Grifols, in the Nordic countries. Gunilla Lundmark has extensive experience from the pharmaceutical industry, including the position head of Q-Med Australia, with responsibility for Australia and New Zealand. ?We are extremely satisfied with the recruitment of Gunilla Lundmark as CEO of Pharmanest. At the same time, we would like to thank Anders Åsell for his invaluable contribution at Pharmanest since the company was founded in 2009. Gunilla Lundmark has years of experience from research, development and marketing of pharmaceuticals and medical device products and will become a valuable asset to the company,? says Bengt Å Johansson, chairman of the Board of Directors for Pharmanest.

Pharmanest aims to create a platform for development of new methods of topical anesthesia in obstetrics and gynecology.